AngioDynamics touts FDA win for "disruptive" clot-reducing catheter

Thu, 08/30/2012 - 3:29pm
Mass Device

The FDA clears AngioDynamics' BioFlo peripheral vascular access catheter system, the 1st such devices to include catheter-related blood clots.

AngioDynamics logo

AngioDynamics (NSDQ:ANGO) won FDA clearance for its BioFlo peripherally-inserted central catheters, the company announced this week.

BioFlo is AngioDynamics' 1st device to include the proprietary Endexo technology for reducing the accumulation of blood clots on and in the catheter, according to a press release.

The Albany, N.Y.-based device maker plans to initiate commercial launch in the U.S. within the next 30 days.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.